Drug name - Fintepla

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10947183 ZOGENIX INC Fenfluramine compositions and methods of preparing the same
Dec, 2036

(14 years from now)

CN108883399A ZOGENIX INC Fenfluramine Composition And Preparation Method Thereof
Dec, 2036

(14 years from now)

CN108883399B ZOGENIX INC Faffluramine Composition And Preparation Method Thereof
Dec, 2036

(14 years from now)

EP3393655A4 ZOGENIX INC Fenfluramine Compositions And Methods Of Preparing The Same
Dec, 2036

(14 years from now)

EP3393655A1 ZOGENIX INC Fenfluramine Compositions And Methods Of Preparing The Same
Dec, 2036

(14 years from now)

EP3393655B1 ZOGENIX INC Fenfluramine Compositions And Methods Of Preparing The Same
Dec, 2036

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478442 ZOGENIX INC Method for the treatment of Dravet Syndrome May, 2033

(10 years from now)

US9603815 ZOGENIX INC Method for the treatment of Dravet syndrome May, 2033

(10 years from now)

US9549909 ZOGENIX INC Method for the treatment of dravet syndrome May, 2033

(10 years from now)

US10478441 ZOGENIX INC Method for the treatment of Dravet syndrome May, 2033

(10 years from now)

US9610260 ZOGENIX INC Method for the treatment of Dravet Syndrome May, 2033

(10 years from now)

US9603814 ZOGENIX INC Method for the treatment of Dravet syndrome May, 2033

(10 years from now)

US10950331 ZOGENIX INC Control system for control of distribution of medication Sep, 2035

(13 years from now)

US10603290 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same Aug, 2037

(14 years from now)

US11040018 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same Aug, 2037

(14 years from now)

US10452815 ZOGENIX INC Control system for control of distribution of medication Jun, 2038

(15 years from now)

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Treatment: Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution; Use in combination with cannabidiol for the treatment of seizures associated with dravet syndrome; Use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.2MG BASE/ML SOLUTION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.